Published online Oct 22, 2018. doi: 10.5497/wjp.v7.i1.1
Peer-review started: July 29, 2018
First decision: September 3, 2018
Revised: September 5, 2018
Accepted: October 12, 2018
Article in press: October 13, 2018
Published online: October 22, 2018
Core tip: Fibromyalgia a multifaceted disorder remains a major unmet condition with current therapies providing limited control. An involvement of potassium channels in the pathophysiology of fibromyalgia and the related symptoms is emerging, and Kv7 channel activators, such as flupirtine and retigabine, exhibit pharmacological profiles compatible with the requirements of therapeutic approaches to fibromyalgia. Focused clinical trials with flupirtine and retigabine will provide important insight to the role of potassium channels and the utility of Kv7 channel activators in fibromyalgia.